Indian pharmaceutical companies play a vital role in supplying affordable generic medicines to the U.S. market. According to a recent report by the IQVIA Institute, Indian companies accounted for 47% of all generic prescriptions used by U.S. patients in 2022, making them the clear leader ahead of the U.S. (30%),...
India’s Biocon Approved for the First Generic Version of liraglutide Injectible
Headquartered in Bangalore, Biocon Ltd, a leading Indian pharmaceutical company, is positioning itself in the weight loss drug market as patents for some blockbuster obesity medications are set to expire. The company has secured approval from the UK's regulatory authority for the first generic version of liraglutide, an injectable drug...
Aurigene Pharmaceutical to Invest in India’s Genome Valley
Aurigene Discovery Technologies Limited, a research, development, and manufacturing services organization and subsidiary of Dr. Reddy's Laboratories, announced plans to construct a development and manufacturing facility for therapeutic proteins, antibodies, and viral vectors in Genome Valley at Hyderabad, India. As the first phase of investment, Aurigene will invest $40 million...
Dr.Reddys, Prestige BioPharma to Supply Herceptin Biosimilar
Hyderabad, India-based Dr. Reddy's Laboratories Ltd., and Prestige BioPharma Ltd., a Singapore-based firm, entered into an exclusive partnership for the supply and commercialization of the latter's proposed Trastuzumab biosimilar, in select countries. Trastuzumab (HD201) is a proposed biosimilar to Roche’s Herceptin and can be prescribed for the treatment of HER2...
India’s Intas to Supply Biosimilar to Spain’s Syna Therapeutics
Ahmedabad, India-headquartered Intas Pharmaceuticals Ltd., signed an exclusive global licensing deal with Syna Therapeutics, a joint venture of Reig Jofre and Leanbio headquartered at Barcelona Science Park, Spain. Syna will develop and manufacture LB-0702 that is used to treat pathologies in the field of hematology, Intas will commercialize this...
Biocon Biologics Signs Licensing Agreement with Yoshindo
Biocon Biologics Ltd., a subsidiary of Bangalore, India-headquartered Biocon Ltd., announced a strategic out-licensing agreement with Japan-based pharmaceuticals company Yoshindo Inc., for commercializing two of its pipeline biosimilar assets. Under the terms of this deal, Biocon Biologics will receive an upfront license fee as well as additional payments on the...